Study: NCT04952753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Investigational drug NIS793 will be administered intravenously (IV) at the dose and schedule determined in the safety run-in part.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: Bevacizumab will be administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be administered IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified FOLFOX6
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified FOLFOX6
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and oxaliplatin \[administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRI
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: 5-fluorouracil \[continuous infusion\], leucovorin \[administered IV\] (or levoleucovorin \[administered IV\]), and irinotecan \[administered IV\]

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Investigational drug tislelizumab will be administered intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Investigational drug tislelizumab will be administered intravenously (IV).